Diabetes News

A data-driven approach could improve the way future costs are predicted for people with type 2 diabetes and Medicare, according to a study published in BMC Endocrine Disorders.

In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease, both with and without type 2 diabetes.

The SGLT2 inhibitor empagliflozin improved CV and renal outcomes in patients with HF with reduced ejection fraction, regardless of diabetes status, according to results of the EMPEROR-Reduced trial.

Glucose management remains important for adults with diabetes and advanced chronic kidney disease as a strategy to prevent or delay progression to dialysis, prevent cardiovascular events and improve quality of life, according to a speaker.

Type 1 diabetes does not increase risk for hospitalization from COVID-19, particularly among individuals without diabetes complications, according to an analysis of hospital data.

A study of patients with type 2 diabetes demonstrated those who had an increased progression of chronic kidney disease, as measured by eGFR, also had a higher likelihood of experiencing major adverse cardiovascular events.

For patients with type 2 diabetes and obesity, undergoing Roux-en-Y gastric bypass surgery led to greater remission rates of albuminuria and early stage chronic kidney disease compared with best medical care.

Smoking modestly increased the risk for severe disease in hospitalized patients with COVID-19, particularly among younger patients without diabetes, according to a systematic review and meta-analysis.

The SGLT2 inhibitor dapagliflozin was linked to significant reductions in worsening renal function and renal or cardiovascular death in adults with chronic kidney disease irrespective of type 2 diabetes, according to a press release.

In collaboration with the National Committee for Quality Assurance, the National Kidney Foundation has developed a kidney health evaluation measure designed specifically for patients with diabetes.